Enlivex Therapeutics Ltd. (ENLV.TA)
ILA 433.2
(5.2%)
ILA 433.2
(5.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 30.63 Million USD | 18.75% |
| 2022 | 25.79 Million USD | 33.75% |
| 2021 | 19.28 Million USD | 97.12% |
| 2020 | 9.78 Million USD | 13.53% |
| 2019 | 8.61 Million USD | 62.65% |
| 2018 | 5.29 Million USD | -11.02% |
| 2017 | 5.95 Million USD | -62.47% |
| 2016 | 15.86 Million USD | 2.52% |
| 2015 | 15.47 Million USD | 118.59% |
| 2014 | 7.08 Million USD | 516.72% |
| 2013 | 1.14 Million USD | 407.96% |
| 2012 | 226 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.95 Million USD | -35.15% |
| 2024 Q2 | 2.98 Million USD | -24.41% |
| 2023 Q2 | 6.64 Million USD | -1.98% |
| 2023 Q1 | 6.78 Million USD | -13.54% |
| 2023 Q3 | 5.62 Million USD | -15.36% |
| 2023 Q4 | 6.09 Million USD | 8.23% |
| 2023 FY | 30.63 Million USD | 18.75% |
| 2022 Q2 | 5.87 Million USD | -8.32% |
| 2022 Q3 | 5.67 Million USD | -3.3% |
| 2022 Q4 | 7.84 Million USD | 38.19% |
| 2022 FY | 25.79 Million USD | 33.75% |
| 2022 Q1 | 6.4 Million USD | -18.04% |
| 2021 Q4 | 7.81 Million USD | 102.23% |
| 2021 FY | 19.28 Million USD | 97.12% |
| 2021 Q3 | 3.86 Million USD | 1.47% |
| 2021 Q2 | 3.8 Million USD | 0.16% |
| 2021 Q1 | 3.8 Million USD | 2.84% |
| 2020 Q1 | 1.89 Million USD | -33.22% |
| 2020 Q4 | 3.69 Million USD | 88.72% |
| 2020 Q3 | 1.95 Million USD | -12.27% |
| 2020 FY | 9.78 Million USD | 13.53% |
| 2020 Q2 | 2.23 Million USD | 17.77% |
| 2019 Q2 | 1.29 Million USD | -45.09% |
| 2019 FY | 8.61 Million USD | 62.65% |
| 2019 Q4 | 2.83 Million USD | 33.85% |
| 2019 Q3 | 2.12 Million USD | 63.53% |
| 2019 Q1 | 2.36 Million USD | 14.22% |
| 2018 Q4 | 2.06 Million USD | 66.64% |
| 2018 FY | 5.29 Million USD | -11.02% |
| 2018 Q1 | 1.14 Million USD | 94.88% |
| 2018 Q2 | 848 Thousand USD | -25.74% |
| 2018 Q3 | 1.24 Million USD | 46.34% |
| 2017 Q2 | 1.65 Million USD | -37.46% |
| 2017 Q1 | 2.64 Million USD | -14.12% |
| 2017 FY | 5.95 Million USD | -62.47% |
| 2017 Q4 | 586 Thousand USD | -45.64% |
| 2017 Q3 | 1.07 Million USD | -34.71% |
| 2016 Q1 | 4.49 Million USD | -7.06% |
| 2016 Q4 | 3.07 Million USD | -32.85% |
| 2016 Q3 | 4.57 Million USD | 23.0% |
| 2016 Q2 | 3.72 Million USD | -17.14% |
| 2016 FY | 15.86 Million USD | 2.52% |
| 2015 Q3 | 3.58 Million USD | -4.04% |
| 2015 Q2 | 3.73 Million USD | 12.66% |
| 2015 Q4 | 4.83 Million USD | 34.74% |
| 2015 Q1 | 3.31 Million USD | 3.78% |
| 2015 FY | 15.47 Million USD | 118.59% |
| 2014 Q3 | 2.13 Million USD | 91.55% |
| 2014 Q4 | 3.19 Million USD | 50.09% |
| 2014 Q1 | 641 Thousand USD | -18.24% |
| 2014 Q2 | 1.11 Million USD | 73.48% |
| 2014 FY | 7.08 Million USD | 516.72% |
| 2013 Q3 | 192 Thousand USD | 43.28% |
| 2013 FY | 1.14 Million USD | 407.96% |
| 2013 Q2 | 134 Thousand USD | 0.0% |
| 2013 Q4 | 784 Thousand USD | 308.33% |
| 2012 FY | 226 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Matricelf Ltd | 11.78 Million ILA | -159.932% |